查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046920

罕見血友病因子市場－全球產業規模、佔有率、趨勢、機會、預測：依療法、類型、地區和競爭格局分類，2021-2031年

Rare Hemophilia Factors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Type By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球罕見血友病因子市場預計將從 2025 年的 3.4511 億美元大幅成長至 2031 年的 5.0669 億美元，複合年成長率為 6.61%。

此市場涵蓋用於治療A型和B型血友病以外的其他遺傳性凝血障礙的專用療法，尤其針對因子I、II、V、VII、X、XI和XIII缺乏症。市場成長的主要驅動力是基因組檢測技術的進步，該技術能夠實現更早期、更準確的診斷，以及新型治療方法的推出，這些療法具有作用持續時間更長、給藥頻率更低的優勢。

市場概覽
預測期 2027-2031
市場規模：2025年 3.4511億美元
市場規模：2031年 5.0669億美元
複合年成長率：2026-2031年 6.61%
成長最快的細分市場 因子濃縮物
最大的市場 北美洲

然而，市場擴張面臨許多挑戰，尤其是這些疾病的極度罕見性以及症狀表現的多樣性，使得識別患者變得極為困難。這種診斷缺口不僅限制了潛在患者群體，也使新療法的臨床開發過程更加複雜。例如，根據美國國家出血性疾病基金會估計，到2025年，遺傳性X因子缺乏症在全球的發病率將達到五十萬分之一到百萬分之一，這凸顯了建立患者登記系統和確保患者持續獲得專業醫療服務的固有困難。

市場促進因素

罕見血友病治療藥物監管核准流程的加速推進，顯著降低了治療方法超罕見出血性疾病的准入門檻，從而極大地促進了市場成長。監管機構正日益採用加速核准流程並授予孤兒藥資格，以促進針對少數患者疾病的治療方法的研發。美國食品藥物管理局的一個典型例證。這表明，FDA 致力於應對罕見疾病臨床試驗面臨的獨特挑戰，同時提供經濟獎勵和市場獨佔權。

同時，重組療法和半衰期延長療法的進步正在透過提高安全性和患者便利性來革新治療方式。從冷沉澱物向高純度血漿衍生和重組濃縮物的持續轉變正在改善止血效果並提高患者的生活品質。例如，正如2025年7月在美國血液學會（ASH）年會上宣布的那樣，一項纖維蛋白原濃縮物的III期臨床試驗顯示，接受治療的患者總體止血成功率高達98.9%。這些臨床上的進步正在直接推動新產品的商業化。例如，正如Griffols公司在2025年12月宣布的那樣，FDA核准了FESILTY（一種用於治療先天性纖維蛋白原缺乏症急性出血的新型纖維蛋白原濃縮物），這進一步拓展了罕見凝血障礙的治療選擇。

市場挑戰

全球罕見血友病因子市場成長的主要限制因素在於，由於此類疾病極為罕見且症狀多樣，準確識別和診斷患者面​​臨巨大挑戰。這種診斷缺口直接阻礙了市場擴張，人為地限制了目標患者群體的規模，從而降低了開發特化血漿衍生和重組療法的商業性可行性。此外，難以獲得足夠數量的確診患者也對臨床開發構成重大障礙。製藥公司難以招募合格臨床實驗的受試者，最終導致新療法的核准和上市延遲。

許多地區普遍缺乏完善的病患登記系統，這進一步加劇了上述問題。這使得製造商難以準確預測需求，也難以證明服務如此有限的市場所需的高昂製造成本的合理性。全球登記資料充分體現了這種識別困難的嚴重性。例如，世界血友病聯盟在2024年底報告稱，全球「其他出血性疾病」（包括這些罕見的凝血因子缺乏症）類別中確診的患者總數僅為83,451例。與全球人口相比，如此低的確診病例數凸顯了漏診對市場收入成長和長期永續性造成的持續障礙。

市場趨勢

居家和自我給藥治療模式的擴展正在從根本上改變全球罕見血友病因子市場的患者管理方式，顯著降低了患者對醫療機構進行常規輸液的依賴。這一趨勢的特點是開發出易於使用的給藥系統和皮下製劑，使患者能夠在家中舒適地管理因子VII、X和XIII缺乏症。這種向分散式護理的轉變不僅提高了患者的依從性，而且隨著製造商優先考慮以患者為中心的設計，也顯著促進了商業活動。 2025年1月，BioSpace預測，到2035年，凝血蛋白疾病市場的複合年成長率將達到8.2%，主要得益於居家治療方案和穿戴式監測設備的普及。

同時，基於藥物動力學的個人化給藥方案正逐漸成為最佳化罕見凝血因子缺乏症治療效果的關鍵策略。與標準的固定劑量方案不同，這種先進的方法能夠根據每位患者獨特的代謝特徵客製化凝血因子替代療法，直接應對諸如因子XIII缺乏症等疾病中顯著的表現型波動。這種精準醫療模式確保在維持適當谷濃度的同時，最大限度地減少藥物浪費，鑑於目前特殊濃縮製劑的短缺，這一點尤其重要。 2025年2月出版的《血栓與止血研討會》指出，嚴重因子XIIIA缺乏症的估計發病率僅為兩百萬分之一，這凸顯了基於藥物動力學的個體化替代療法對於有效控制不可預測的出血模式的迫切需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：罕見血友病因子全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（凝血因子濃縮物、新鮮冷凍血漿、冷沉澱物、其他）
    • 依類型（因子 I、因子 II、因子 V、因子 VII、因子 X、因子 XI、因子 XIII）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美罕見血友病因子市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲罕見血友病因子市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區罕見血友病因子市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲罕見血友病因子市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲罕見血友病因子市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球罕見血友病因子市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novo Nordisk A/S
  • Bayer AG
  • Pfizer, Inc.
  • Shire Pharmaceuticals
  • CSL Behring
  • Bio Products Laboratory Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Alexion Pharmaceuticals, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 21661

The Global Rare Hemophilia Factors Market is projected to expand significantly, growing from USD 345.11 million in 2025 to USD 506.69 million by 2031, at a compound annual growth rate (CAGR) of 6.61%. This market encompasses specialized therapeutic agents designed to treat inherited coagulation disorders beyond Hemophilia A and B, specifically targeting deficiencies in Factors I, II, V, VII, X, XI, and XIII. Market growth is primarily driven by advances in genomic testing, which enable earlier and more accurate diagnoses, alongside the introduction of novel therapies that offer extended durations of action, thereby reducing the frequency of administration.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 345.11 Million
Market Size 2031USD 506.69 Million
CAGR 2026-20316.61%
Fastest Growing SegmentFactor Concentrates
Largest MarketNorth America

However, market expansion faces considerable challenges, notably the profound difficulty in identifying affected patients due to the extreme rarity and diverse symptomatic presentations of these conditions. This diagnostic gap not only limits the potential patient base but also complicates the process of clinical development for new treatments. For instance, hereditary Factor X deficiency was estimated to affect only about one in 500,000 to one in one million people globally in 2025, according to the National Bleeding Disorders Foundation, highlighting the inherent difficulties in establishing patient registries and ensuring consistent access to specialized care.

Market Driver

Accelerated regulatory approvals for orphan hemophilia drugs are significantly propelling market growth by easing the entry barriers for therapies addressing ultra-rare bleeding disorders. Regulatory bodies are increasingly adopting expedited pathways and granting orphan drug designations to incentivize the development of treatments for conditions with limited patient populations. This regulatory support is exemplified by decisions like the US FDA granting Orphan Drug Designation to Coagulation Factor X human (Coagadex) for acquired Factor X Deficiency in July 2025, as reported by Kedrion Biopharma, which provides financial incentives and market exclusivity while signaling a willingness to accommodate the unique challenges of rare disease clinical trials.

Simultaneously, advancements in recombinant and extended half-life therapies are revolutionizing the treatment landscape by offering enhanced safety profiles and greater convenience for patients. The ongoing transition from cryoprecipitate to highly purified plasma-derived and recombinant concentrates is improving hemostatic outcomes and elevating patient quality of life. For example, a Phase III study of a fibrinogen concentrate demonstrated an impressive 98.9% overall hemostatic success rate in treated patients, according to the American Society of Hematology in July 2025. These clinical improvements are directly fueling the commercialization of new products, such as the FDA's approval of FESILTY, a novel fibrinogen concentrate for acute bleeding episodes in congenital fibrinogen deficiency, as announced by Grifols in December 2025, further broadening the therapeutic options available for rare coagulation disorders.

Market Challenge

A primary impediment to the growth of the Global Rare Hemophilia Factors Market is the considerable challenge in accurately identifying and diagnosing patients, stemming from the extreme rarity and varied symptoms of these conditions. This diagnostic void directly hinders market expansion by artificially constraining the size of the addressable patient population, thereby diminishing the commercial viability of developing specialized plasma-derived and recombinant therapies. Furthermore, the inability to locate a sufficient number of confirmed patients creates substantial obstacles for clinical development, as pharmaceutical companies struggle to recruit eligible individuals for trials, which ultimately delays the approval and market launch of new treatments.

Compounding this issue is the widespread absence of comprehensive patient registries in many regions, which complicates manufacturers' efforts to forecast demand accurately or to justify the high production costs associated with serving such a limited market. The magnitude of this identification crisis is evident in global registry figures; for instance, the World Federation of Hemophilia reported in late 2024 that the total number of identified patients worldwide with "other bleeding disorders"-a category that includes these rare factor deficiencies-was only 83,451. This low volume of identified patients, when contrasted with the global population, highlights the persistent barrier that under-diagnosis poses to market revenue growth and long-term sustainability.

Market Trends

The expansion of home-based and self-administration treatment models is fundamentally transforming patient management within the Global Rare Hemophilia Factors Market by significantly reducing the reliance on clinical settings for routine infusions. This trend is characterized by the development of user-friendly delivery systems and subcutaneous formulations that empower patients to manage deficiencies in Factors VII, X, and XIII comfortably within their own homes. This shift toward decentralized care is not only improving patient adherence but also stimulating substantial commercial activity as manufacturers prioritize patient-centric designs; BioSpace, in January 2025, projected an 8.2% CAGR for the coagulation protein disorders market through 2035, heavily driven by the adoption of home-based treatment options and wearable monitoring devices.

Concurrently, the implementation of pharmacokinetic-guided personalized dosing is emerging as a critical strategy to optimize therapeutic efficacy for ultra-rare coagulation deficits. Unlike standard fixed-dose regimens, this advanced approach customizes factor replacement schedules to match each patient's unique metabolic profile, directly addressing the significant phenotypic variability observed in disorders like Factor XIII deficiency. This precision medicine model ensures that adequate trough levels are maintained while simultaneously minimizing product wastage, which is particularly vital given the scarcity of specialized concentrates. Seminars in Thrombosis and Hemostasis, in February 2025, noted that the estimated incidence of severe Factor XIII-A deficiency is only one per 2 million individuals, underscoring the necessity of such personalized pharmacokinetic-based replacement therapies for effectively managing unpredictable bleeding patterns.

Key Market Players

  • Novo Nordisk A/S
  • Bayer AG
  • Pfizer, Inc.
  • Shire Pharmaceuticals
  • CSL Behring
  • Bio Products Laboratory Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Alexion Pharmaceuticals, Inc.

Report Scope

In this report, the Global Rare Hemophilia Factors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rare Hemophilia Factors Market, By Treatment

  • Factor Concentrates
  • Fresh Frozen Plasma
  • Cryoprecipitate
  • Others

Rare Hemophilia Factors Market, By Type

  • Factor I
  • Factor II
  • Factor V
  • Factor VII
  • Factor X
  • Factor XI
  • Factor XIII

Rare Hemophilia Factors Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rare Hemophilia Factors Market.

Available Customizations:

Global Rare Hemophilia Factors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rare Hemophilia Factors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate, Others)
    • 5.2.2. By Type (Factor I, Factor II, Factor V, Factor VII, Factor X, Factor XI, Factor XIII)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Rare Hemophilia Factors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rare Hemophilia Factors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Type
    • 6.3.2. Canada Rare Hemophilia Factors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Type
    • 6.3.3. Mexico Rare Hemophilia Factors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Type

7. Europe Rare Hemophilia Factors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Rare Hemophilia Factors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Type
    • 7.3.2. France Rare Hemophilia Factors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Type
    • 7.3.3. United Kingdom Rare Hemophilia Factors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Type
    • 7.3.4. Italy Rare Hemophilia Factors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Type
    • 7.3.5. Spain Rare Hemophilia Factors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Type

8. Asia Pacific Rare Hemophilia Factors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Rare Hemophilia Factors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Type
    • 8.3.2. India Rare Hemophilia Factors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Type
    • 8.3.3. Japan Rare Hemophilia Factors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Type
    • 8.3.4. South Korea Rare Hemophilia Factors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Type
    • 8.3.5. Australia Rare Hemophilia Factors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Type

9. Middle East & Africa Rare Hemophilia Factors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Rare Hemophilia Factors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Type
    • 9.3.2. UAE Rare Hemophilia Factors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Type
    • 9.3.3. South Africa Rare Hemophilia Factors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Type

10. South America Rare Hemophilia Factors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rare Hemophilia Factors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Type
    • 10.3.2. Colombia Rare Hemophilia Factors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Type
    • 10.3.3. Argentina Rare Hemophilia Factors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Rare Hemophilia Factors Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novo Nordisk A/S
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bayer AG
  • 15.3. Pfizer, Inc.
  • 15.4. Shire Pharmaceuticals
  • 15.5. CSL Behring
  • 15.6. Bio Products Laboratory Ltd.
  • 15.7. Takeda Pharmaceutical Co. Ltd.
  • 15.8. Alexion Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer